Government plans to replace the Drugs & Cosmetics Act, 1940. This highlights a major regulatory shift. The Draft Drugs, Medical Devices & Cosmetics Bill, 2026 aims to replace the 1940 Act. It will consolidate drug, device, and cosmetic regulation under one law. It introduces a dedicated medical devices framework with risk-based classification. This will empower the DCGI with binding authority over state regulators. Additionally, it enforces stricter bail provisions for spurious or adulterated drugs. Thus, the government positions the proposed bill as a modernization move to streamline approvals and recalls. However, medical device associations are opposing it, arguing that the Bill remains pharma-centric. Moreover, it imposes disproportionate criminal penalties for technical lapses and could discourage innovation and investment. This sets the stage for intense debate between regulators and industry stakeholders over the future of India’s compliance landscape.
Draft Drugs, Medical Devices & Cosmetics Bill, 2026: A major regulatory shift
The Draft Drugs, Medical Devices & Cosmetics Bill, 2026 is India’s most ambitious regulatory overhaul in decades. It is set to repeal the 1940 Act. It will introduce a dedicated medical devices framework, empower the DCGI (renamed as Drugs & Medical Devices Controller General), tighten bail provisions for spurious/adulterated drugs, and streamline approvals and recalls. However, it faces strong opposition from medical device associations who argue it remains pharma-centric and risks stifling innovation.
SUBMIT
Key features of the Draft Drugs, Medical Devices & Cosmetics Bill, 2026
Innovation risks
By applying pharma-style compliance to devices, the Draft Drugs, Medical Devices & Cosmetics Bill, 2026, may slow down adoption of emerging technologies, such as Al-driven diagnostics and advanced imaging systems. Industry leaders fear that startups will be burdened with complex approvals and harsh penalties. This could stifle India’s competitiveness in the fast-evolving medtech sector.
Conclusions
Draft Drugs, Medical Devices & Cosmetics Bill, 2026 represents a landmark attempt to modernize India’s regulatory framework by consolidating oversight of drugs, devices, and cosmetics under one law. Its provisions, such as risk-based device classification, expanded DCGI powers, stricter bail conditions, and trial waivers, signal a push towards stronger compliance and faster innovation pathways. However, industry stakeholders remain deeply concerned that the Bill’s pharma-centric language and disproportionate criminal penalties could stifle medical device growth and deter investment. The debate now hinges on whether India will refine the Bill to balance enforcement with innovation or risk creating a regulatory environment that prioritizes control over competitiveness. Thus, the outcome will shape India’s ability to position itself as a global hub for pharmaceuticals and medtech in the coming decade.
Source: Pharmadocx
